Drug Profile
CLR 2100 - Cellectar Biosciences/Onconova Therapeutics
Alternative Names: CLR 2100 - ribosomal inhibitor - Cellectar Biosciences/Onconova Therapeutics; PDC™; Phospholipid ether-drug conjugates - Cellectar Biosciences/Onconova TherapeuticsLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Cellectar Biosciences; Onconova Therapeutics
- Class Antineoplastics; Drug conjugates; Phospholipid ethers; Small molecules
- Mechanism of Action Ribosomal protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 09 Mar 2021 Cellectar Biosciences has patent protection for Phospholipid-ether analogues in Japan
- 12 Jun 2020 Cellectar Biosciences has patent pending for composition of matter and use of phospholipid-ether analogs in Europe